ZA200709091B - Erythropoietin variants - Google Patents

Erythropoietin variants

Info

Publication number
ZA200709091B
ZA200709091B ZA200709091A ZA200709091A ZA200709091B ZA 200709091 B ZA200709091 B ZA 200709091B ZA 200709091 A ZA200709091 A ZA 200709091A ZA 200709091 A ZA200709091 A ZA 200709091A ZA 200709091 B ZA200709091 B ZA 200709091B
Authority
ZA
South Africa
Prior art keywords
erythropoietin variants
erythropoietin
variants
Prior art date
Application number
ZA200709091A
Other languages
English (en)
Inventor
Meisel Andreas
Priller Josef
Bonnas Christel
Dirnagl Ulrich
Original Assignee
Charite Universitaetsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin filed Critical Charite Universitaetsmedizin
Publication of ZA200709091B publication Critical patent/ZA200709091B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200709091A 2005-05-13 2007-10-22 Erythropoietin variants ZA200709091B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants

Publications (1)

Publication Number Publication Date
ZA200709091B true ZA200709091B (en) 2009-08-26

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709091A ZA200709091B (en) 2005-05-13 2007-10-22 Erythropoietin variants

Country Status (12)

Country Link
EP (2) EP1736481A1 (https=)
JP (1) JP5231214B2 (https=)
KR (1) KR101468737B1 (https=)
CN (1) CN101175768B (https=)
AU (1) AU2006245916B2 (https=)
BR (1) BRPI0608769A2 (https=)
CA (1) CA2608379C (https=)
DK (1) DK1885747T3 (https=)
ES (1) ES2457398T3 (https=)
RU (1) RU2430162C2 (https=)
WO (1) WO2006120030A1 (https=)
ZA (1) ZA200709091B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
WO2008137636A2 (en) * 2007-05-02 2008-11-13 University Of Utah Research Foundation Compositions and methods for identifying and treating subjects at risk of developing type 2 diabetes
DE102007031708A1 (de) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
KR101931403B1 (ko) 2011-09-23 2018-12-21 블루버드 바이오, 인코포레이티드. 개선된 유전자 치료 방법
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
EP2953473B1 (en) 2013-02-06 2018-11-28 Nc Medical Research Inc. Method of producing a heterogeneous subpopulation of bone marrow cells suitable for the treatement of neurodegeneration cased by ischemic stroke
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
CA2995733A1 (en) * 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Aav-epo for treating companion animals
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
EP3916008A1 (en) * 2020-05-26 2021-12-01 Sylus Co., Ltd. New peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
CN117940451A (zh) * 2021-06-15 2024-04-26 安德烈马肯有限公司 Epo变体和调节剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants

Also Published As

Publication number Publication date
CA2608379A1 (en) 2006-11-16
AU2006245916A1 (en) 2006-11-16
CN101175768B (zh) 2013-09-11
EP1885747A1 (en) 2008-02-13
JP5231214B2 (ja) 2013-07-10
KR20080021595A (ko) 2008-03-07
EP1885747B1 (en) 2013-11-20
CN101175768A (zh) 2008-05-07
BRPI0608769A2 (pt) 2010-01-26
CA2608379C (en) 2014-12-16
AU2006245916B2 (en) 2012-03-15
WO2006120030A1 (en) 2006-11-16
EP1736481A1 (en) 2006-12-27
ES2457398T3 (es) 2014-04-25
DK1885747T3 (en) 2014-02-24
JP2008539745A (ja) 2008-11-20
WO2006120030A8 (en) 2006-12-28
KR101468737B1 (ko) 2014-12-09
RU2007146455A (ru) 2009-06-20
RU2430162C2 (ru) 2011-09-27

Similar Documents

Publication Publication Date Title
ZA200709091B (en) Erythropoietin variants
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006013270D1 (en) Prrs-impfstoffe
DE602006017073D1 (en) Aspartylproteasehemmer
EP1871379A4 (en) CYANOARYLAMINE
IL232923A0 (en) Enhanced erythropoietin
DE602006016951D1 (en) 2-cyanoacrylatzusammensetzung
DE502006002219D1 (en) Rotationspumpe
DE602006015303D1 (en) Lecknachweisflicken
GB0512249D0 (en) Hayfit3
GB0506636D0 (en) Lipdiscreet
GB0505768D0 (en) Spare-AD2
GB0520466D0 (en) Smartwash
AU4036P (en) Dottie Calathea roseo-picta
AU3621P (en) Scacover Scaevola aemula
GB0516150D0 (en) Improved smpsogi
GR1007111B (en) Assembled ballot-box
GB0508278D0 (en) Specnoculars
GB0500259D0 (en) Drydam
GB0511335D0 (en) Grach
GB0512490D0 (en) Fascines
GB0508124D0 (en) Drydam
GB0508039D0 (en) Smartshare
GB0507456D0 (en) Stethograph
GB0507312D0 (en) Cad-cover